Literature DB >> 1317344

Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C.

S Brillanti1, C Masci, P Ricci, M Miglioli, L Barbara.   

Abstract

We assessed the correlation between the positivity for serum IgM antibody to hepatitis C virus and the activity of liver disease in patients with chronic hepatitis C virus infection. Serum samples were taken from 10 antibody to hepatitis C virus-positive asymptomatic patients with normal serum ALT levels, from 14 untreated patients with clinically and histologically proven chronic hepatitis C and from 26 patients with clinically and histologically proven chronic hepatitis C assigned to receive recombinant interferon alpha-2a (6 million IU three times a week for 6 mo). Each serum specimen was tested for IgM antibody to hepatitis C virus-associated C100-3 antigen by enzyme-linked immunosorbent assay. Patients were observed for at least 12 mo. All 10 patients with normal ALT values tested negative for IgM antibody to hepatitis C virus. In contrast, 33 of 40 (82%) patients with chronic hepatitis C had IgM antibody to hepatitis C virus, and a positive correlation was seen between the ALT level and the level of IgM antibody to hepatitis C virus (r = 0.803, p less than 0.001). During interferon treatment, ALT levels declined into the normal range in 18 of 26 treated patients (69%) and remained normal after stopping treatment in 8 patients (31%). In untreated patients, in treated patients who did not respond to interferon treatment and in responder patients who relapsed, no significant changes in IgM antibody to hepatitis C virus levels were seen during the study period. In contrast, IgM antibody to hepatitis C virus became undetectable by the end of interferon treatment in seven of eight patients with a sustained response.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317344     DOI: 10.1002/hep.1840150604

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

Review 1.  Hepatitis C in childhood.

Authors:  F Bortolotti
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

2.  Clinical study of IgA antibody against hepatitis C virus core antigen in patients with type C chronic liver disease.

Authors:  M Tanaka; S Sato; S Fujiyama; S Kawano; Y Taura; H Chikazawa; Y Honda; J Shibata; T Sato
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

3.  Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C.

Authors:  M Mohler; S Seipp; U Tox; W Stremmel; L Theilmann; T Goeser
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

Review 4.  Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups.

Authors:  H L Tillmann; M P Manns
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  IgG1 anti-P2 as a marker of response to interferon in patients with chronic hepatitis C.

Authors:  M Hirayama; T Maruyama; H Mitsui; H Maekawa; H Yamada; N Hashimoto; K Koike; S Kimura; K Yasuda; S Iino; J Green
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

6.  Distinguishing acute from chronic and resolved hepatitis C virus (HCV) infections by measurement of anti-HCV immunoglobulin G avidity index.

Authors:  S Klimashevskaya; A Obriadina; T Ulanova; G Bochkova; A Burkov; A Araujo; Susan L Stramer; Leslie H Tobler; Michael P Busch; Howard A Fields
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

Review 7.  Viral markers in the treatment of hepatitis B and C.

Authors:  H Schmilovitz-Weiss; M Levy; N Thompson; G Dusheiko
Journal:  Gut       Date:  1993       Impact factor: 23.059

8.  IgM and IgG antibodies to hepatitis C virus in patients with mixed cryoglobulinaemia.

Authors:  A L'Abbate; S Cutrupi; M Rognetta; C Fabiano; A Craxi
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

9.  Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA.

Authors:  O Yokosuka; N Kato; K Hosoda; Y Ito; F Imazeki; M Ohto; M Omata
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

10.  Establishment and application of SPA-co-operated ELISA for detection of anti-HCV-IgM.

Authors:  F H Li; L S Guo; Z Q Yu; Y K Wang; J Y Qi; X W Yuan; L J Hao
Journal:  J Tongji Med Univ       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.